Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Colloidal silver "cure-all" OTC products not safe and effective -- FDA proposed rule.

This article was originally published in The Tan Sheet

Executive Summary

COLLOIDAL SILVER-CONTAINING OTC PRODUCTS LACK SAFETY/EFFICACY DATA and would be misbranded under a proposed rule published by FDA in an Oct. 15 Federal Register notice. Comments on whether the substance can be generally recognized as safe and effective (GRAS) may be submitted to the agency within 90 days. Colloidal silver historically has been marketed with claims to treat a number of disease conditions.
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS086236

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel